Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 9/20 | 0.51 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | EDNRA | P25101 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.42 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31239603 | 0.82 | MCL1 (0.56) | CCR2TP53HPGDTSHRMCL1 | |
| SCHEMBL4589791 | 0.82 | MCL1 (0.56) | CCR2TP53HPGDTSHRMCL1 | |
| SCHEMBL6335085 | 0.81 | AKR1B1 (0.56) | TRPV4HSD11B1AKR1B1TP53EDNRA | |
| SCHEMBL2646455 | 0.80 | L3MBTL1 (0.39) | CCR2TRPV4 | |
| SCHEMBL12186139 | 0.80 | L3MBTL1 (0.44) | CCR2HSD11B1MCL1 | |
| SCHEMBL8405133 | 0.80 | L3MBTL1 (0.59) | CCR2TRPV4 | |
| SCHEMBL11963208 | 0.79 | AKR1B1 (0.46) | TRPV4HSD11B1AKR1B1TP53EDNRA | |
| Hydrochloric Acid SCHEMBL11256201 | 0.79 | AKR1B1 (0.54) | TRPV4HSD11B1AKR1B1TP53EDNRA | |
| SCHEMBL29519358 | 0.79 | TRPV4 (0.57) | TRPV4HSD11B1AKR1B1TP53EDNRA | |
| SCHEMBL444929 | 0.79 | TRPV4 (0.57) | TRPV4HSD11B1AKR1B1TP53EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20210238164-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-08-05 | — | — | US | disclosed |
| WO-2021032033-A1 | PYRIDAZINOL COMPOUND, DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE THEREOF | 青岛清原化合物有限公司 | 2021-02-25 | — | — | WO | disclosed |
| US-10189812-B2 | Bi-benzyl isoquinoline derivative, preparation method and use thereof in hepatopathy treatment and prevention | THE KEY LABORATORY OF CHEMISTRY FOR NATURAL PRODUC (CN) | 2019-01-29 | — | — | US | disclosed |
| US-20170260161-A1 | BI-BENZYL ISOQUINOLINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF IN HEPATOPATHY TREATMENT AND PREVENTION | VERSITECH LIMITED (CN) | 2017-09-14 | — | — | US | disclosed |
| US-20170260161-A1 | BI-BENZYL ISOQUINOLINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF IN HEPATOPATHY TREATMENT AND PREVENTION | VERSITECH LIMITED (CN) | 2017-09-14 | — | — | US | disclosed |
| WO-2017129944-A1 | TRACER AND METHOD | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-08-03 | — | — | WO | disclosed |
| EP-2925743-B1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2016-02-03 | — | — | EP | disclosed |
| US-9169251-B2 | Pyrrolopyridine derivatives and their use as CRTH2 antagonists | NOVARTIS AG (CH) | 2015-10-27 | — | — | US | disclosed |
| US-9169251-B2 | Pyrrolopyridine derivatives and their use as CRTH2 antagonists | NOVARTIS AG (CH) | 2015-10-27 | — | — | US | disclosed |
| EP-1326864-A2 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 2003-07-16 | — | — | EP | disclosed |
| EP-1326606-A2 | EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS | PFIZER PHARMACEUTICALS INC. (JP) | 2003-07-16 | — | — | EP | disclosed |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PFIZER PHARMACEUTICALS INC. (JP) | 2002-06-20 | — | — | US | disclosed |
| WO-2002032422-A2 | EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
| WO-2002032900-A2 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
| EP-0351332-B1 | HERBICIDAL COMPOUNDS AND COMPOSITIONS CONTAINING THEM | RHONE-POULENC AGROCHIMIE (FR) | 1993-03-24 | — | — | EP | disclosed |
| US-5117064-A | Selective | FUJI PHOTO FILM CO., LTD. (JP) | 1992-05-26 | — | — | US | disclosed |
| US-5100460-A | HERBICIDAL COMPOUNDS AND COMPOSITIONS CONTAINING THEM | RHONE-POULENC AGROCHIMIE (FR) | 1992-03-31 | — | — | US | disclosed |
| EP-0351332-A1 | Herbicidal compounds and compositions containing them | RHONE-POULENC AGROCHIMIE (FR) | 1990-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260161-A1 | BI-BENZYL ISOQUINOLINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF IN HEPATOPATHY TREATMENT AND PREVENTION | SLC10A1, SLC10A2, CYP4B1 | CCR2 1381/4885TRPV4 2819/4885HSD11B1 162/4885 |
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | CCR2 713/4885TRPV4 497/4885HSD11B1 1060/4885 |
| US-20210238164-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | CCR2 713/4885TRPV4 497/4885HSD11B1 1060/4885 |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | CCR2 22/4885TRPV4 73/4885HSD11B1 260/4885 |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PTGER4, PTGER1, PTGER2 | CCR2 256/4885TRPV4 125/4885HSD11B1 1994/4885 |
| US-10189812-B2 | Bi-benzyl isoquinoline derivative, preparation method and use thereof in hepatopathy treatment and prevention | SLC10A1, SLC10A2, CYP4B1 | CCR2 1381/4885TRPV4 2819/4885HSD11B1 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.